知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.022 秒)

    Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
    2.
    发明申请
    Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof 审中-公开
    抗CD137抗体作为治疗癌症及其糖基化变体的药物

    公开(公告)号：US20060182744A1

    公开(公告)日：2006-08-17

    申请号：US11058458

    申请日：2005-02-15

    申请人： Scott Strome ,  Daniel Schindler ,  Lieping Chen ,  Harry Meade ,  Yann Echelard

    发明人： Scott Strome ,  Daniel Schindler ,  Lieping Chen ,  Harry Meade ,  Yann Echelard

    IPC分类号： A61K39/395 ,  C07K16/30

    CPC分类号： C07K16/2878 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/734

    摘要： The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as an anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred imbodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals.

    摘要翻译： 本发明涉及重组激动抗体抗人CD137及其糖基化变体的开发和使用方法。 这些抗体作为有效减少实体瘤或其他癌症适应症并预防其复发的抗癌剂和/或免疫调节剂。 预期抗体对其治疗有效的癌症类型还包括白血病和淋巴瘤。 在优选的实施方案中，本发明的重组抗体在转基因动物的牛奶中制备和纯化。

    Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
    4.
    发明申请
    Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection 审中-公开
    使用抗CD137抗体作为放射免疫治疗或放射免疫检测试剂的方法

    公开(公告)号：US20080019905A9

    公开(公告)日：2008-01-24

    申请号：US11061295

    申请日：2005-02-18

    申请人： Scott Strome ,  Daniel Schindler ,  Lieping Chen ,  Harry Meade ,  Yann Echelard

    发明人： Scott Strome ,  Daniel Schindler ,  Lieping Chen ,  Harry Meade ,  Yann Echelard

    IPC分类号： A61K51/00 ,  C07K16/46

    CPC分类号： A61K51/1096

    摘要： The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred imbodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers.

    摘要翻译： 本发明涉及重组激动抗体抗人CD137及其糖基化变体的开发和使用方法。 这些抗体作为有效减少实体瘤或其他癌症适应症并防止其复发的抗癌剂和/或免疫调节剂。 预期抗体对其治疗有效的癌症类型还包括白血病和淋巴瘤。 在优选的实施方案中，本发明的重组抗体在转基因动物的牛奶中制备和纯化。 在本发明的另一个优选实施方案中，本发明的激动性抗CD137抗体可以与放射性核素缀合以用于放射免疫检测或放射免疫治疗目的，或与毒素结合以增强各种癌症的治疗性治疗。

    Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
    5.
    发明申请
    Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection 审中-公开
    使用抗CD137抗体作为放射免疫治疗或放射免疫检测试剂的方法

    公开(公告)号：US20060188439A1

    公开(公告)日：2006-08-24

    申请号：US11061295

    申请日：2005-02-18

    申请人： Scott Strome ,  Daniel Schindler ,  Lieping Chen ,  Harry Meade ,  Yann Echelard

    发明人： Scott Strome ,  Daniel Schindler ,  Lieping Chen ,  Harry Meade ,  Yann Echelard

    IPC分类号： A61K51/00 ,  C07K16/46

    CPC分类号： A61K51/1096

    摘要： The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred imbodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers.

    摘要翻译： 本发明涉及重组激动抗体抗人CD137及其糖基化变体的开发和使用方法。 这些抗体作为有效减少实体瘤或其他癌症适应症并防止其复发的抗癌剂和/或免疫调节剂。 预期抗体对其治疗有效的癌症类型还包括白血病和淋巴瘤。 在优选的实施方案中，本发明的重组抗体在转基因动物的牛奶中制备和纯化。 在本发明的另一个优选实施方案中，本发明的激动性抗CD137抗体可以与放射性核素缀合以用于放射免疫检测或放射免疫治疗目的，或与毒素结合以增强各种癌症的治疗性治疗。

    GLYCOSYLATION ENGINEERED ANTIBODY THERAPY
    7.
    发明申请
    GLYCOSYLATION ENGINEERED ANTIBODY THERAPY 审中-公开
    糖蛋白工程抗体治疗

    公开(公告)号：US20100173323A1

    公开(公告)日：2010-07-08

    申请号：US12304080

    申请日：2007-06-09

    申请人： Scott Strome ,  Lai-Xi Wang

    发明人： Scott Strome ,  Lai-Xi Wang

    IPC分类号： G01N33/53 ,  C12P21/06 ,  C07K16/00 ,  G01N33/566

    CPC分类号： C07K16/2863 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/53 ,  C07K2317/72 ,  C07K2317/732

    摘要： The instant invention is drawn to methods of generating a glycosylation-engineered antibody, and using the glycosylation-engineered antibody for treating a patient, particularly a cancer patient or a patient with an immune disease or disorder. The instant invention is also drawn to methods of generating a glycosylation-engineered antibody for use in the treatment of patients having a polymorphism that does not respond to conventional antibody therapy. The instant invention is also drawn to methods of improving the biological activity of an antibody by glycosylation engineering. The instant invention is also drawn to methods of modulating antibody-dependent cell-mediated cytoxicity (ADCC) using a glycosylation-engineered antibody.

    摘要翻译： 本发明涉及生成糖基化工程化抗体的方法，并使用糖基化工程改造的抗体治疗患者，特别是癌症患者或具有免疫疾病或病症的患者。 本发明还涉及产生糖基化工程化抗体的方法，所述抗体用于治疗具有不符合常规抗体疗法的多态性的患者。 本发明还涉及通过糖基化工程改进抗体的生物学活性的方法。 本发明还涉及使用糖基化工程化抗体调节抗体依赖性细胞介导的细胞毒性（ADCC）的方法。

    METHODS FOR TREATING CANCERS AND DISEASES ASSOCIATED WITH 4-1BB (CD137) EXPRESSION
    9.
    发明申请
    METHODS FOR TREATING CANCERS AND DISEASES ASSOCIATED WITH 4-1BB (CD137) EXPRESSION 审中-公开
    用于治疗与4-1BB（CD137）表达相关的癌症和疾病的方法

    公开(公告)号：US20120076722A1

    公开(公告)日：2012-03-29

    申请号：US13320267

    申请日：2010-05-11

    申请人： Scott Strome ,  Xiaoyu Zhang

    发明人： Scott Strome ,  Xiaoyu Zhang

    IPC分类号： A61K39/395 ,  A61K51/00 ,  C12Q1/68 ,  G01N21/75 ,  G01N33/566 ,  A61P37/04 ,  A61K38/17

    CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K16/2875 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/76

    摘要： The present invention relates to the role of 4-1BB (CD137) ligand and anti-4-1BB (CD137) antibody in the treatment of cancers and diseases associated with 4-1BB (CD137) expression. More particularly, the present invention relates to the use of (i) 4-1BB (CD137) ligand for inducing proliferation and activation and promoting survival of B lymphocytes and (2) anti-4-1BB (anti-CD137) antibody for inhibiting proliferation and activation and inducing death of B lymphocytes.

    摘要翻译： 本发明涉及4-1BB（CD137）配体和抗4-1BB（CD137）抗体在治疗与4-1BB（CD137）表达相关的癌症和疾病中的作用。 更具体地说，本发明涉及（i）4-1BB（CD137）配体诱导B淋巴细胞的增殖和激活和促进​​存活的用途，和（2）抗4-1BB（抗CD137）抗体用于抑制增殖 并激活和诱导B淋巴细胞死亡。